The breakout success of GLP-1 drugs by Novo Nordisk and Eli Lilly has persuaded many of their Big Pharma peers to enter their own newly acquired candidates into the obesity race. But don’t expect Novartis to be joining them anytime soon.
“Coming in late with another one of the oral or injectable GLP [or] GIPs, we think is not a prudent approach for us as a company,” Novartis CEO Vas Narasimhan, M.D., told analysts on a second-quarter earnings call this morning.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,